Heney N M, Nocks B N
J Urol. 1982 Jul;128(1):18-20. doi: 10.1016/s0022-5347(17)52730-5.
Records of patients with renal cell carcinoma extending into the inferior vena cava were reviewed. Patients with nodal metastases or distal spread were excluded, leaving 19 cases available for analysis. The over-all 3 and 5-year survival rates were 56 and 38 per cent, respectively, but a striking difference in survival was observed when those patients with perinephric fat involvement (T3ac) were separated from those whose tumours had not penetrated through the renal capsule (T3c). The 3 and 5-year survival rates for patients with T3ac tumors were 14 and 0 per cent, compared to 82 and 67 per cent for patients with T3c tumors. Patients with T3ac tumors had metastases earlier (mean 13 months) than patients with T3c tumors (mean 22 months). The over-all mean survival duration was 50 months. However, the mean survival duration of patients with T3ac tumors was 17 months, compared to 75 months for patients with T3c tumors.
对肾细胞癌侵犯下腔静脉的患者记录进行了回顾。排除有淋巴结转移或远处转移的患者,剩余19例可供分析。总体3年和5年生存率分别为56%和38%,但当将有肾周脂肪受累(T3ac)的患者与肿瘤未穿透肾包膜(T3c)的患者分开时,观察到生存情况有显著差异。T3ac肿瘤患者的3年和5年生存率分别为14%和0%,而T3c肿瘤患者的这一数据分别为82%和67%。T3ac肿瘤患者出现转移的时间(平均13个月)早于T3c肿瘤患者(平均22个月)。总体平均生存时间为50个月。然而,T3ac肿瘤患者的平均生存时间为17个月,而T3c肿瘤患者为75个月。